Fetroja
Drug
Shionogi Inc
Total Payments
$6.0M
Transactions
17,686
Doctors
5,028
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.3M | 5,616 | 2,356 |
| 2023 | $738,558 | 4,695 | 2,107 |
| 2022 | $1.4M | 4,234 | 1,942 |
| 2021 | $488,754 | 2,070 | 1,132 |
| 2020 | $896,206 | 513 | 263 |
| 2019 | $1.2M | 558 | 93 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.0M | 254 | 50.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1.2M | 362 | 19.6% |
| Consulting Fee | $991,945 | 342 | 16.4% |
| Food and Beverage | $498,547 | 15,490 | 8.3% |
| Travel and Lodging | $159,118 | 600 | 2.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $62,336 | 28 | 1.0% |
| Space rental or facility fees (teaching hospital only) | $43,400 | 23 | 0.7% |
| Grant | $31,718 | 1 | 0.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $21,510 | 23 | 0.4% |
| Education | $11,201 | 563 | 0.2% |
Payments by Type
Research
$3.0M
254 transactions
General
$3.0M
17,432 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Assessment of the In Vivo Efficacy of Cefiderocol against Gram-Negative Bacteria under iron-depleted and iron-overloaded conditions in the Neutropenic Murine Thigh infection model | Shionogi Inc | $884,011 | 0 |
| In Vivo Efficacy of Cefiderocol Alone and in Combination with Meropenem, Ceftazidime/Avibactam or Tigecycline against Acinetobacter baumannii in the Neutropenic Murine Thigh Infection Model | Shionogi Inc | $304,603 | 0 |
| A retrospective chart review study of cefiderocol real world outcomes and safety in the treatment of patients with Gram-negative bacterial infections (GNBI) in the US and Europe | Shionogi Inc | $267,149 | 0 |
| Effect of Continuous Renal Replacement Therapy and Residual Renal Clearance on Cefiderocol Pharmacokinetics in Critically Ill Adult Patients | Shionogi Inc | $223,721 | 0 |
| Clinical Study of S-649266 for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens APEKS-NP | Shionogi Inc | $216,648 | 0 |
| Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia | Shionogi Inc | $198,651 | 0 |
| Population Pharmacokinetics of Cefiderocol during Acute Pulmonary Exacerbations in Adult Patients with Cystic Fibrosis | Shionogi Inc | $184,437 | 0 |
| An Open-label Study With a Nonrandomized Single-dose Phase in Subjects With Suspected or Confirmed Aerobic Gram-negative Bacterial Infections Followed by a Randomized, Multiple-dose, Active-controlled Phase in Subjects With Suspected or Confirmed Complicated Urinary Tract Infection (cUTI), to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Subjects 3 Months to < 18 Years of Age | Shionogi Inc | $121,431 | 0 |
| Ex vivo Sequestration and Pharmacokinetics of Cefiderocol in Critically ill patients receiving Extracorporeal membrane oxygenation (ECMO)e | Shionogi Inc | $103,130 | 0 |
| In Vitro Activity of Cefiderocol against a Contemporary, Global Collection of Carbapenem-Resistant Pseudomonas aeruginosa with a High Level of Carbapenemase Diversity | Shionogi Inc | $76,179 | 0 |
| SRA202103-0008 | Shionogi Inc | $75,003 | 0 |
| Molecular mechanisms of cefiderocol resistance in Acinetobacter baumannii | Shionogi Inc | $70,701 | 0 |
| Clinical Study of S-649266 for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens (APEKS-NP) | Shionogi Inc | $68,299 | 0 |
| Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens CREDIBLE - CR | Shionogi Inc | $61,312 | 0 |
| (CRAB Acinetobacter) retrospective cohort study of patients infected with acinetobacter 2017 - 2018 & expanded access protocol | Shionogi Inc | $48,750 | 0 |
| SRA202111-0005 | Shionogi Inc | $37,068 | 0 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants | Shionogi Inc | $29,184 | 0 |
| Performance of Cefiderocol Susceptibility Testing Methods Against Target Gram-Negative Pathogens | Shionogi Inc | $22,606 | 0 |
| Shionogi Cefiderocol with PER | Shionogi Inc | $19,500 | 0 |
| CRAB Acinetobacter retrospective cohort study of patients infected with acinetobacter 2017 - 2018 & expanded access protocol | Shionogi Inc | $16,250 | 0 |
Top Doctors Receiving Payments for Fetroja
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Francisco, CA | $3.3M | 327 |
| , MD | Internal Medicine | Sacramento, CA | $228,861 | 211 |
| , M.D | Critical Care Medicine | Augusta, GA | $143,476 | 108 |
| , D.O | Infectious Disease | Altamonte Springs, FL | $133,891 | 154 |
| , M.D | Infectious Disease | Sylmar, CA | $117,342 | 138 |
| , MD | Internal Medicine | Whitehouse Station, NJ | $107,622 | 13 |
| , MD, MPH | Infectious Disease | Roseville, CA | $104,454 | 73 |
| , M.D | Internal Medicine | Livingston, NJ | $84,284 | 83 |
| , MD | Cardiovascular Disease | Baton Rouge, LA | $68,849 | 66 |
| , M.D | Infectious Disease | Boston, MA | $66,058 | 38 |
| , M.D | Critical Care Medicine | Brooklyn, NY | $63,898 | 67 |
| , MD | Pediatrics | Caldwell, NJ | $60,342 | 28 |
| , MD, MS | Internal Medicine | Dallas, TX | $57,795 | 71 |
| , M.D | Specialist | Livonia, MI | $47,199 | 30 |
| Gordon Corey | — | Durham, NC | $45,140 | 4 |
| , M.D | Infectious Disease | Atlanta, GA | $44,035 | 27 |
| , MD | Student in an Organized Health Care Education/Training Program | Ashland, KY | $41,741 | 38 |
| , MD | Pulmonary Disease | Chicago, IL | $40,991 | 31 |
| , MD | Pulmonary Disease | Saint Louis, MO | $37,230 | 19 |
| , MD | Internal Medicine | Detroit, MI | $34,991 | 30 |
| , M.D | Infectious Disease | Santa Monica, CA | $33,541 | 33 |
| , M.D | Internal Medicine | New York, NY | $32,395 | 38 |
| , MD, PHARMD | Student in an Organized Health Care Education/Training Program | Pittsburgh, PA | $32,349 | 55 |
| , MD | Pulmonary Disease | Washington, DC | $31,670 | 24 |
| , MD | Student in an Organized Health Care Education/Training Program | Shreveport, LA | $31,087 | 50 |
Ad
Manufacturing Companies
- Shionogi Inc $6.0M
Product Information
- Type Drug
- Total Payments $6.0M
- Total Doctors 5,028
- Transactions 17,686
About Fetroja
Fetroja is a drug associated with $6.0M in payments to 5,028 healthcare providers, recorded across 17,686 transactions in the CMS Open Payments database. The primary manufacturer is Shionogi Inc.
Payment data is available from 2019 to 2024. In 2024, $1.3M was paid across 5,616 transactions to 2,356 doctors.
The most common payment nature for Fetroja is "Unspecified" ($3.0M, 50.2% of total).
Fetroja is associated with 20 research studies, including "Assessment of the In Vivo Efficacy of Cefiderocol against Gram-Negative Bacteria under iron-depleted and iron-overloaded conditions in the Neutropenic Murine Thigh infection model" ($884,011).